Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis

References

• Abbate GF, Alagia I, Giaquinto E, et al. Treatment of lower respiratory tract infections with ceftriaxone and cefotaxime. A comparative study. Respiration. 1986;49:222–230.
   PubMed Web of Science ®Google Scholar
• Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30:397–404.
   PubMed Web of Science ®Google Scholar
• File TM Jr., Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii19–32.
   PubMed Web of Science ®Google Scholar
• Low DE, File TM Jr., Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33–44.
   PubMed Web of Science ®Google Scholar
• Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15:161–171.
   PubMed Web of Science ®Google Scholar
• Owens RC Jr., Tessier P, Nightingale CH, et al. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2001;17:483–489.
   PubMed Web of Science ®Google Scholar
• Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47:421–429.
   PubMed Web of Science ®Google Scholar
• Simon N, Dussol B, Sampol E, et al. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet. 2006;45:493–501.
   PubMed Web of Science ®Google Scholar
• Goto K, Sato Y, Yasuda N, et al. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy. J Basic Clin Physiol Pharmacol. 2016;27:625–631.
   PubMedGoogle Scholar
• Seddon M, Wise R, Gillett AP, et al. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980;18:240–242.
   PubMed Web of Science ®Google Scholar
• Garot D, Respaud R, Lanotte P, et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011;72:758–767.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
   PubMedGoogle Scholar
• Nicholson SC, Welte T, File TM Jr., et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240–246.
   PubMed Web of Science ®Google Scholar
• Petermann W, Alegre-Martin J, Odenholt I, et al. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia. Scand J Infect Dis. 2001;33:832–837.
   PubMedGoogle Scholar
• Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008;46:1142–1151.
   PubMed Web of Science ®Google Scholar
• Torres A, Garau J, Arvis P, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study–a randomized clinical trial. Clin Infect Dis. 2008;46:1499–1509.
   PubMed Web of Science ®Google Scholar
• Welte T, Petermann W, Schurmann D, et al., Group MS. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005;41:1697–1705.
   PubMed Web of Science ®Google Scholar
• Talaie H, Jabari HR, Shadnia S, et al. Cefepime/clindamycin vs. ceftriaxone/clindamycin for the empiric treatment of poisoned patients with aspiration pneumonia. Acta Biomed. 2008;79:117–122.
   PubMedGoogle Scholar
• San Pedro GS, Cammarata SK, Oliphant TH, et al., Linezolid Community-Acquired Pneumonia Study G. . Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis. 2002;34:720–728.
   PubMed Web of Science ®Google Scholar
• Zervos M, Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group. Antimicrob Agents Chemother. 1998;42:729–733.
   PubMed Web of Science ®Google Scholar
• Grossman RF, Campbell DA, Landis SJ, et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother. 1999;43:549–554.
   PubMed Web of Science ®Google Scholar
• Dansey RD, Jacka PJ, Strachan SA, et al. Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia. Diagn Microbiol Infect Dis. 1992;15:81–84.
   PubMed Web of Science ®Google Scholar
• Bittner MJ, Pugsley MP, Horowitz EA, et al. Randomised comparison of ceftriaxone and cefamandole therapy in lower respiratory tract infections in an elderly population. J Antimicrob Chemother. 1986;18:621–627.
   PubMed Web of Science ®Google Scholar
• de Klerk GJ, van Steijn JH, Lobatto S, et al. A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections. Int J Antimicrob Agents. 1999;12:121–127.
   PubMed Web of Science ®Google Scholar
• Lode H, File TM Jr., Mandell L, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther. 2002;24:1915–1936.
   PubMed Web of Science ®Google Scholar
• Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther. 2002;24:1292–1308.
   PubMed Web of Science ®Google Scholar
• Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, et al.; Protocol 018 Ertapenem Community-Acquired Pneumonia Study G. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002;34:1076–1083.
   PubMed Web of Science ®Google Scholar
• Ortiz-Ruiz G, Vetter N, Isaacs R, et al. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother. 2004;53(Suppl 2):ii59–66.
   PubMedGoogle Scholar
• Vetter N, Cambronero-Hernandez E, Rohlf J, et al., Protocol 020 Study G. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther. 2002;24:1770–1785.
   PubMed Web of Science ®Google Scholar
• Woods GL, Isaacs RD, McCarroll KA, et al. Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc. 2003;51:1526–1532.
   PubMed Web of Science ®Google Scholar
• Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med. 2004;3:329–336.
   PubMedGoogle Scholar
• Paladino JA, Eubanks DA, Adelman MH, et al. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia. J Am Geriatr Soc. 2007;55:651–657.
   PubMed Web of Science ®Google Scholar
• Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65:713–716.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–2152.
   PubMed Web of Science ®Google Scholar
• Andreatos N, Flokas ME, Apostolopoulou A, et al. The dose-dependent efficacy of cefepime in the empiric management of febrile neutropenia: A systematic review and meta-analysis. Open Forum Infect Dis. 2017;4:ofx113.
   PubMed Web of Science ®Google Scholar
• Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefu- roxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11:315–317.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Legrand P, Philippon A, et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet. 1987;ii:302–306.
   Google Scholar
• Figueiredo-Mello C, Naucler P, Negra MD, et al. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial. Clin Microbiol Infect. England. 2018 Feb;24(2):146–151.
   PubMed Web of Science ®Google Scholar